Back to Search
Start Over
Staphylococcus capitis and NRCS-A clone: the story of an unrecognized pathogen in neonatal intensive care units.
- Source :
-
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [Clin Microbiol Infect] 2019 Sep; Vol. 25 (9), pp. 1081-1085. Date of Electronic Publication: 2019 Mar 27. - Publication Year :
- 2019
-
Abstract
- Background: In neonatal intensive care units (NICUs), nosocomial late-onset sepsis (LOS), mostly due to coagulase negative staphylococci, constitute a major cause of death or impairment. Staphylococcus capitis, usually considered as a poorly virulent species, has been reported as a cause of LOS.<br />Objectives: To review data regarding S. capitis neonatal LOS and the features of isolates involved.<br />Sources: PubMed was searched up to August 2018 to retrieve studies on the topic; the keywords used were 'S. capitis', 'neonate', 'neonatal ICU', 'bloodstream infection' and 'late onset sepsis'.<br />Content: Published data highlight the worldwide endemicity of a single S. capitis clone, named NRCS-A, specifically involved in LOS. NRCS-A harbours a multidrug resistance profile (including resistance to the usual first-line antibiotics used in NICUs). It is also able to adapt under vancomycin selective pressure that could confer an advantage for its implantation and dissemination in NICUs where this selective pressure is high. Moreover, a severe morbidity has been observed in NRCS-A-related LOS. The NICU environment, and especially incubators, constitute reservoirs of NRCS-A from which it could diffuse inside the setting. Finally, the virulome and resistome of S. capitis NRCS-A contain many genes potentially implicated in its specific epidemiology and pathophysiology, including the gene nsr that may be involved in its fitness and implantation in neonatal gut flora.<br />Implications: S. capitis must be considered as a true pathogen in neonates. The decreased susceptibility to vancomycin may be involved in failure of vancomycin therapy. Further studies are needed to better manage its diffusion inside each NICU but also worldwide.<br /> (Copyright © 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Subjects :
- Anti-Bacterial Agents pharmacology
Anti-Bacterial Agents therapeutic use
Drug Resistance, Multiple, Bacterial genetics
Humans
Infant, Newborn
Sepsis drug therapy
Sepsis physiopathology
Sepsis transmission
Staphylococcal Infections drug therapy
Staphylococcal Infections physiopathology
Staphylococcal Infections transmission
Staphylococcus capitis drug effects
Vancomycin pharmacology
Vancomycin therapeutic use
Virulence genetics
Intensive Care Units, Neonatal
Sepsis microbiology
Staphylococcal Infections microbiology
Staphylococcus capitis genetics
Staphylococcus capitis pathogenicity
Subjects
Details
- Language :
- English
- ISSN :
- 1469-0691
- Volume :
- 25
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 30928561
- Full Text :
- https://doi.org/10.1016/j.cmi.2019.03.009